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ABSTRACT
Objective To assess the effect of continuous positive
airway pressure (CPAP) on 24 hour ambulatory blood
pressure monitoring values in a large number of patients
with untreated systemic hypertension of new onset and
obstructive sleep apnoea.
DesignMulticentre, double blind, randomised, placebo
controlled trial.
Setting Eleven general hospitals in Spain between 2004
and 2007.
Participants 340 patients recently diagnosed as having
systemic hypertension by a general practitioner (systolic
blood pressure ≥140 mm Hg, diastolic blood pressure
≥90mmHg, or both) and an apnoea-hypopnoea index per
hour of sleep of >15 events/hour.
Intervention Patients were assigned to CPAP (n=169) or
sham CPAP (n=171) for three months.
Main outcome measurements Net changes in the
different 24 hour ambulatory blood pressure monitoring
values from baseline to three months of optimal or sham
CPAP.
Results 277 (81%) of the 340 patients randomised were
men; the patients had amean age of 52.4 (SD10.5) years,
a body mass index of 31.9 (5.7), an Epworth sleepiness
scale score of 10.1 (4.3), an apnoea-hypopnoea index of
43.5 (24.5). No differences between groups were seen at
baseline. Compared with placebo and analysed by
intention to treat, the mean 24 hour ambulatory blood
pressure of the CPAP group decreased by 1.5 (95%
confidence interval: 0.4 to 2.7) mm Hg (P=0.01). The
mean 24 hour ambulatory blood pressure monitoring
measures decreased by 2.1 mm Hg (0.4 to 3.7) mm Hg
(P=0.01) for systolic pressure and 1.3 (0.2 to 2.3) mm Hg
(P=0.02) for diastolic blood pressure. Mean nocturnal
blood pressure decreased by 2.1 (0.5 to 3.6) mm Hg
(P=0.01).
Conclusions CPAP produced a statistically significant
reduction in blood pressure in patients with systemic
hypertension and obstructive sleep apnoea. This
reduction is small and did not achieve the 3 mm Hg drop
in mean 24 hour ambulatory blood pressure that the trial
was powered to detect. Consequently, these results may
have uncertain clinical relevance. However, taking into
account the prevalence of hypertension and the
likelihood of comorbidities, the decrease in blood
pressure, although minimal, may be beneficial.
Trial registration Clinical trials NCT00202527.
INTRODUCTION
Obstructive sleep apnoea is a common disorder, char-
acterised by repetitive episodes of upper airway
obstruction, which can cause poor health status with
increased comorbidity and mortality, primarily due
to cardiovascular causes.1-10 Systemic hypertension
hasbeen suggested as oneof themajor causes of cardio-
vascular disease in patients with obstructive sleep
apnoea, and large scale epidemiological studies have
shown that obstructive sleep apnoea is associated
with systemic hypertension and cardiovascular
complications.2 11-14 However, few high quality pro-
spective observational studies have examined this
question, and only two longitudinal studies have been
done. One of these found a clear association between
obstructive sleep apnoea and new cases of systemic
hypertension,11 and the other failed to show any
association.15 In this second study, systemic hyperten-
sion was seen only in overweight patients.15 The data
on the incidence of the disease are therefore not clear,
probably primarily owing to associated comorbidities
such as obesity.
Continuous positive airway pressure (CPAP) is the
best treatment for obstructive sleep apnoea16; the most
accepted indication for CPAP is symptomatic obstruc-
tive sleep apnoea. Theoretically, if obstructive sleep
apnoea is a cause of systemic hypertension, CPAP
treatment should improve blood pressure control.
Randomised clinical trials can confirm this hypothesis,
and data from systematic reviews and meta-analyses
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show a small but consistent reduction in blood
pressure.16-21 However, the effect of CPAP treatment
on blood pressure was highly variable. This heteroge-
neity could have several causes: most of the studies
were done in small samples; almost all the studies
were done in single institutions, reflecting local charac-
teristics;most studies have been carried out inmen; the
methods used for measuring blood pressure (24 hour
ambulatory blood pressure monitoring or office blood
pressure measurement) varied between the studies;
studies included patients with and without hyperten-
sion, as well as different types of hypertension and
treatments; the methods used to establish a diagnosis
of obstructive sleep apnoea and the definition of
hypopnoeas varied; the presence or absence of hyper-
somnolence and the criteria used for its evaluation or
concomitant comorbidity varied; the studies had either
crossover or parallel designs; studies used pills, sham
CPAP, sub-therapeutic CPAP, or conservative treat-
ment in control participants; and the duration of treat-
ment varied between one and 52 weeks. In summary,
meta-analyses of randomised trials are only as good as
the trials on which they are based, and many of the
trials were not done in the patients most likely to ben-
efit, which could explain the heterogeneity of the
results. The greatest benefit is likely to be seen in
patients with obstructive sleep apnoea who already
have untreated systemic hypertension and are thus
likely to be more sensitive to treatment of systemic
hypertension as a result of amelioration of obstructive
sleep apnoea.
As systemic hypertension and obstructive sleep
apnoea are very commondiseases with highmorbidity
and mortality, clarifying the effect of CPAP on these
patients is very important. Accordingly, our study has
been designed to minimise the limitations and short-
comings seen in previous studies and to use an ade-
quate number of patients. We did a multicentre
controlled trial in patients with moderate to severe
obstructive sleep apnoea and recently diagnosed but
untreated systemic hypertension. We aimed to assess
whether CPAP treatment produces a significant reduc-
tion in 24 hour ambulatory blood pressure and
whether it could play an important role in the treat-




We included men and women aged between 18 and
75 years who had just been diagnosed as having sys-
temic hypertension by a general practitioner using cuff
measurements,8 but had not been treated, and who
were habitual snorers. We excluded patients if they
had secondary systemic hypertension, had blood pres-
sure over 180/110 mm Hg, had cognitive deteriora-
tion, were professional drivers or handled dangerous
machinery, worked shifts, were pregnant, or had life
threatening obstructive sleep apnoea or a severe
chronic disease. We also excluded patients previously
treated for obstructive sleep apnoea and patients with
any contraindication for prescribing CPAP. Patients
who used antihypertensive drugs, psychotropic
drugs, stimulants, antidepressants, or illicit drugs or
drank alcohol to excess were also excluded.
Protocol design
This was a multicentre, randomised, prospective, dou-
ble blind, parallel study controlled by placebo (sham
CPAP) in patients from 11 hospitals in Spain. General
practitioners recruited patients with untreated, newly
diagnosed systemic hypertension and snoring and sent
them to the hospitals’ sleep laboratories. Systemic
hypertension was diagnosed according to standard cri-
teria and was defined as systolic blood pressure of at
least 140 mm Hg, diastolic blood pressure of at least
90 mm Hg, or both.22 Consecutive patients who met
all the inclusion criteria were invited to undergo full
polysomnography. Patients were randomised if they
had an apnoea-hypopnoea index of 15 events/hour
or more. We did a physical examination and recorded
patients’ medical history, and we recorded the
Epworth sleepiness scale and EuroQol scores at base-
line and at six and 12 weeks. We did 24 hour ambula-
tory blood pressure monitoring according to the
standard recommendations.22
An external unit—the Health Research Unit of the
Txagorritxu Hospital—generated the allocation
sequence, using a computerised randomisation proce-
dure. When an eligible patient was identified, the clin-
ician sent the patient’s identification information (date
of birth, sex, and initials) by email, and the group assig-
nation to either optimal therapeutic CPAP or sham
CPAP was returned within 24 hours. Each patient
signed a consent form before being included in the
study, and all patients were informed about both
arms of the trial (CPAP and sham CPAP as placebo—
CPAP at a very low pressure (<1 cmH20) without any
known therapeutic effect). We also ran teaching and
training sessions (with CPAP and sham) before titra-
tion of optimal CPAP. Patients remained blinded as
to whether they were receiving CPAP or sham, and
systemic hypertension was not treated with drugs dur-
ing the study. The doctors and nurses who assessed the
patients in outpatient clinics did not receive any infor-
mation about the treatment arm. ShamCPAPwas pre-
pared separately and distributed to CPAP machines,
with no apparent differences between optimal CPAP
and sham CPAP. We specifically instructed doctors
and nurses not to try to obtain any information that
might indicate which arm of treatment the patient
was assigned to. Only sleep clinic nurses who main-
tained the machines and assisted patients at home
had information about treatment (CPAP v sham), but
they were not involved in outcome assessments. After
six and 12 weeks of treatment, a new 24 hour ambula-
tory blood pressure monitoring measurement was
done, with the patients still on the allocated treatment
(CPAPor sham). Themain outcomevariableswere net
changes in the different 24 hour ambulatory blood
pressure monitoring values from baseline to three
months of optimal or sham CPAP.
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Full overnight polysomnographywas done in the sleep
laboratories of the participating centres according
to international recommendations.23 Sleep stages,
arousal, oxygen saturation, apnoeas, and hypopnoeas
were scored by using conventional criteria.23 24 We
defined an apnoea as a complete (>90%) cessation of
airflow of at least 10 seconds and a hypopnoea as any
discernible reduction in airflow (around 50%) for at
least 10 seconds, along with a drop in oxygen satura-
tion of more than 3%, an electroencephalographic
arousal, or both.We considered the polysomnography
recording to be valid for scoring if the total sleep time
was longer than 180 minutes.
CPAP treatment
We titrated optimal CPAP by using auto-CPAP (Auto-
set-T; ResMed, Sydney, Australia), according to a pre-
vious validation by the Spanish Sleep and Breathing
Group.24 The optimal pressure was determined
visually from the raw data, and patients were sent
homewith this pressure for 12weeks. Patients assigned
to sham CPAP received this treatment at home for
12 weeks, using the method described by Farré et al.25
We assessed compliancewithCPAP (both optimal and
sham) from the device counter. We checked for side
effects and any problems with the treatment at one,
four, six, and 12 weeks.
24 hour ambulatory blood pressure monitoring
Werecorded24hour ambulatory bloodpressuremon-
itoring with a Spacelabs model 90207. The cuff was
programmed to inflate every 20 minutes between
6 am and 10 pm (“daytime”) and every 30 minutes
between 10 pm and 6 am (“night-time”), and the
blood pressure data were processed automatically.
We recorded24hour ambulatory bloodpressuremon-
itoring data at baseline and at six and 12 weeks. We
made the diagnosis of systemic hypertension by 24
hour ambulatory blood pressure monitoring accord-
ing to standard criteria22; we defined it as systolic
blood pressure 135 mm Hg or above, diastolic blood
pressure 85 mm Hg or above, or both during waking
hours and systolic blood pressure 120 mm Hg or
above, diastolic blood pressure 75 mm Hg or above,
or both during sleeping hours.
Database
We designed a database, accessible online, which was
posted in the Respira network of the Spanish Respira-
tory Society (www.redrespira.net). Each participating
centre could access only its own data. The principal
researcher was responsible for sending all the data to
the statistical committee and to external evaluators for
analysis of the results.
Statistical analysis
We used SPSS version 15.0 to analyse data. We
expressed continuous variables as means and standard
deviations and qualitative variables as percentages.
We compared the baseline characteristics of the two
groups (CPAP and sham) by using two tailed unpaired
t tests for continuous variables and χ2 tests for catego-
rical variables.Weused paired t tests to evaluatewithin
group and between group changes in blood pressure






Completed trial (n=135)Completed trial (n=137)
Excluded (n=187):
  Refused to participate (n=94)
  Apnoea-hypopnoea index <15 (n=71)
  Did not meet inclusion criteria (n=22)
Refused to continue
  (n=15) 
Intolerant to CPAP (n=12)
Protocol violation (n=1) 
Technical problems (n=4)
Refused to continue
  (n=18) 
Intolerant to CPAP (n=10)
Protocol violation (n=3) 
Technical problems (n=5)
Fig 1 | Flow diagram of study. CPAP=continuous positive
airway pressure
Table 1 | Characteristics of patients at baseline. Values are means (SD) unless stated
otherwise
Characteristics CPAP (n=169) Sham (n=171)
Age (years) 53.2 (10.2) 51.7 (10.8)
No (%) male 133 (79) 144 (84)
Body mass index (kg/m2) 31.9 (5.7) 31.9 (5.8)
Epworth sleepiness scale (0-24) 10.3 (4.2) 9.8 (4.4)
No (%) active smokers 49 (29) 39 (23)
Alcohol consumption (g/day of ethanol) 22.9 (26.4) 19.7 (22.5)
Caffeine consumption (cups/day of coffee) 1.5 (1.3) 1.5 (1.4)
Office blood pressure:
Systolic blood pressure (mm Hg) 131.1 (11.6) 128.8 (11.4)
Diastolic blood pressure (mm Hg) 82.5 (8.0) 81.8 (8.6)
24 hour ambulatory blood pressure monitoring:
Diurnal systolic blood pressure (mm Hg) 135.1 (12.1) 132.5 (11.3)
Nocturnal systolic blood pressure (mm Hg) 123.3 (13.3) 121.4 (14.1)
Diurnal diastolic blood pressure (mm Hg) 85.7 (8.5) 84.7 (9.2)
Nocturnal diastolic blood pressure (mm Hg) 76.1 (9.1) 76.0 (10.1)
Mean 24 hour blood pressure (mm Hg) 98.7 (8.4) 97.5 (8.9)
No (%) hypertensive 108 (64) 96 (56)
Polysomnographic variables:
Apnoea-hypopnoea index (No/hour of sleep) 44.5 (24.6) 42.5 (24.5)
Mean SaO2 during sleep (%) 89.5 (5.5) 90.1 (4.5)
Lowest SaO2 during sleep (%) 79.9 (9.3) 80.1 (10.6)
Sleep time with SaO2<90% (%) 13.2 (20.3) 10.6 (16.1)
Total sleep (minutes) 448.2 (42.9) 447.6 (45.8)
Sleep N1 (minutes) 47.1 (54.0) 42.2 (42.1)
Sleep N2 (minutes) 207.9 (67.4) 206.4 (70.8)
Sleep N3 (minutes) 39.7 (37.9) 41.9 (40.8)
REM sleep (minutes) 51.0 (29) 52.8 (30)
Arousal from sleep (No/hour of sleep) 39.8 (22.7) 37.2 (24)
CPAP=continuous positive airway pressure; SaO2=arterial oxygen saturation.
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during the follow-up period. We estimated the effect
size at six and 12 weeks by dividing this difference by
the standard deviation of the baseline measurement.
The number of patients needed for the study was set
at 151 participants in each group on the basis of an
assumption of an SD of 7.2 (obtained from a pilot
study) for the change in mean 24 hour ambulatory
blood pressure after CPAP and detection of an effect
of 3 mm Hg or greater between the CPAP and sham
groups,26-28 with a power of 95% and a significance
level of 5%, using a two sided test.
The primary outcome was the net change in 24 hour
ambulatory blood pressure monitoring values from
baseline to three months of optimal or sham CPAP;
we calculated this as the difference in the change (base-
line minus follow-up) in mean values and expressed
the results by intention to treat. Following widely
accepted guidelines,29 we imputed missing data by
using single imputation methods. In our case, we
assumed that when patients withdrew from the study
their blood pressure would return to baseline levels.
Consequently, we used the “baseline observation car-
ried forward” approach, which implies that the
imputed changes in blood pressure for those patients
with no measurements at six or 12 weeks will equal
0 mm Hg (more unfavourable than the mean or med-
ian change observed in either the sham or CPAP arms
of the study). This was, therefore, a very conservative
approach in our context. We are aware that this
approach underestimates the standard errors of the
estimations, and we present all estimations with their
confidence intervals.
An independent committee not involved in the
study (Statistical Service of the Basque Health
Research Institute) did two intermediate analyses,
using the method proposed by O’Brien and
Fleming,30 when 50% and 75% of the sample had com-
pleted the study. Stopping rules were P<0.0030 for
50% and P<0.0163 for 75%. Therefore, to maintain
the overall risk α of the study at the 0.05 level, we set
the value of P for a significant result in the final analysis
<0.0307. We sent the results of these analyses to the
Health Ethics Committee of the Basque Country,
which recommended continuing the study.
RESULTS
Of 527 patients who were screened between Decem-
ber 2004 and June 2007 (fig 1), 187 did not enter the
randomisation process because they refused to partici-
pate (n=94), had an apnoea-hypopnoea indexunder 15
(n=71), or did not meet the inclusion criteria (n=22).
The main cause for refusal to participate was related
to work and scheduling problems for the sleep studies,
24 hour ambulatory blood pressure monitoring, and
medical visits. Finally, 340 patients met the eligibility
criteria, agreed to participate, and were randomised
(87% men, mean age 52.4 (SD 10.5) years, body mass
index 31.9 (5.7), Epworth sleepiness scale score 10.1
(4.3), apnoea-hypopnoea index 43.5 (24.5)); 169
patients were assigned to CPAP and 171 to sham. A
total of 32 (19%) patients in the CPAP group and 36
(21%) in the sham group dropped out. Intolerance of
CPAP caused 12 patients in the CPAP group and 10
patients in the sham group to drop out. Table 1 shows
the baseline characteristics of the two groups, which
were entirely comparable.
Table 2 shows the net change in the CPAP group
compared with the sham group for all the 24 hour
ambulatory blood pressure monitoring variables. The
reduction in mean 24 hour ambulatory blood pressure
at 12weekswas 1.5 (95% confidence interval 0.4 to 2.7)
mmHg (P=0.01) greater in theCPAP group than in the
sham group. The effect was greater for systolic than for
diastolic blood pressure and for nocturnal blood pres-
sure than for diurnal blood pressure. We saw a similar
reduction by the sixth week of the trial (2.3 (1.2 to 3.4)
mm Hg; P<0.001). The results improved when we
restricted them to only patients who had systemic
hypertension as determined by the results of the 24
hour ambulatory blood pressure monitoring, as the
reduction in 24 hour ambulatory blood pressure was
1.7 (0.2 to 3.2) mm Hg (P=0.02) (see web table A).
When we considered only patients who complied
with treatment (objective use of CPAP or sham
CPAP for more than four hours), the 24 hour ambula-
tory blood pressure decreased by 2.2 (0.6 to 3.7) mm
Hg (P=0.01) (see web table B). The results also
improved when analysed by protocol, and the mean
24 hour ambulatory blood pressure of the CPAP
group decreased by 1.9 (0.5 to 3.4) mm Hg (P=0.01)
(see web table C).
Table 3 shows the main data at baseline and after six
and 12weeks ofCPAPor sham treatment. The 24 hour
ambulatory blood pressure monitoring showed statis-
tically significant decreases in most blood pressure
parameters for the CPAP group but not for the sham
group. Figure 2 shows a simplified graphic representa-
tion of the changes in 24 hour ambulatory blood
pressure monitoring from baseline to post-CPAP or
post-sham treatment. We found statistically significant
differences only in the CPAP group. Table 3 also
shows the results of the Epworth sleepiness scale and
the EuroQol scale over time. The Epworth scores
improved significantly in the two groups (CPAP and
sham), but the effect was greater in the CPAP group
(2.2 (1.4 to 3.0); P<0.001). The EuroQol improved
Table 2 | Results of 24 hour ambulatory blood pressure monitoring by changes at 6 and
12 weeks for all fully evaluable patients (CPAP, n=169; sham, n=171)
Blood pressure measurement
Follow-up at 6 weeks Follow-up at 12 weeks
Difference* (95%CI) P value† Difference* (95%CI) P value†
Diurnal systolic blood pressure 2.6 (0.8 to 4.4) 0.004 1.6 (−0.2 to 3.3) 0.07
Diurnal diastolic blood pressure 1.8 (0.7 to 2.9) 0.001 1.1 (−0.1 to 2.3) 0.07
Diurnal mean blood pressure 2.1 (0.8 to 3.3) 0.001 1.3 (−0.1 to 2.5) 0.06
Nocturnal systolic blood pressure 4.1 (2.1 to 6.1) <0.001 3.1 (0.9 to 5.2) 0.005
Nocturnal diastolic blood pressure 2.2 (0.9 to 3.5) <0.001 1.5 (0.1 to 3.0) 0.03
Nocturnal mean blood pressure 2.8 (1.4 to 4.3) <0.001 2.1 (0.5 to 3.6) 0.01
Mean systolic blood pressure 3.1 (1.5 to 4.7) <0.001 2.1 (0.4 to 3.7) 0.01
Mean diastolic blood pressure 1.9 (1.0 to 2.9) <0.001 1.3 (0.2 to 2.3) 0.02
Mean blood pressure 2.3 (1.2 to 3.4) <0.001 1.5 (0.4 to 2.7) 0.01
*Differences in blood pressure (mm Hg) between continuous positive airway pressure (CPAP) and sham groups.
†Calculated by t test; compares treatment effects.
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significantly only in the CPAP group (4.7 (1.2 to 8.1);
P=0.01). We did not find any associations between
blood pressure changes and changes in the Epworth
(P=0.11) or EuroQol scores (P=0.29). We did find a
statistically significant associationbetween compliance
with CPAP and improvements in the Epworth scale
(P=0.01) but not in quality of life as measured with
EuroQol (P=0.05). At baseline, 109 (64%) patients in
the CPAP group and 107 (63%) in the sham group
showed a non-dipping pattern. After 12 weeks, 94
(56%) patients showed this pattern in the CPAP
group (P=0.02), but this change was not apparent in
the sham group. Similarly, we found a statistically sig-
nificant reduction in the percentage of patients with
hypertension only in the CPAP group (P=0.04).
Table 4 shows compliance with CPAP and sham
treatments at six and 12 weeks, expressed in hours
per night, as well as compliance of more than three
and four hours per night. Compliance was similar in
the two groups, and we found no differences over
time between the CPAP and sham groups. The level
of pressure applied in the optimal CPAP groupwas 8.8
(SD1.6) cmH2O.Of 340 patients, 259 (76%) had some
secondary effects from the treatment (124 (73%) in the
CPAP group and 135 (79%) in the sham group). Most
of these effects were mild, short term, and self limiting,
and we found no differences between groups. How-
ever, 12 patients in the CPAP group and 10 in the
sham group discontinued the treatment because of
poor tolerance.
DISCUSSION
This study shows that, in patients with a new diagnosis
of systemic hypertension and obstructive sleep
apnoea, 12 weeks of CPAP treatment significantly
decreased 24 hour ambulatory blood pressure, with a
net reduction of around 2 mm Hg, a decrease that
could affect morbidity and mortality.31 32 This
approach might eventually modify, in certain cases,
the indication for prescribing CPAP.
Comparison with other studies
Two systematic reviews, four meta-analyses including
21 randomised controlled trials, and two recent studies
have evaluated the effect of CPAP treatment on blood
pressure in patients with obstructive sleep
apnoea.16-21 33 34 The results showed a statistically signif-
icant net reduction in blood pressure with CPAP com-
pared with changes in the control group, especially in
patientswithmore severe obstructive sleep apnoea.18 19
However, some studies have shown little or no
effect,35-38 and the results are heterogeneous with
large confidence intervals, from reductions as great as
36 mmHg to increases of 13 mmHg.39 40 In fact, of the
23 studies, only four included more than 100
patients.27 34 35 41 Only some of these trials had good
blood pressure measurements, and few had a pre-spe-
cified primary outcome. Despite these limitations,
obstructive sleep apnoea is now generally recognised
to be a causal risk for systemic hypertension,22
although the association is not as strong as was once
feared.
Some data suggest that people with hypersomno-
lence have a better response to CPAP compared with
other patients,26-28 33 35-39 42 43 although meta-analyses
and our results do not support this.19 Similarly, patients
with hypersomnolence, including more hypertensive
patients, showed greater reduction in blood pressure
with CPAP,33 but this was not uniform and Campos-
Rodriguez et al did not find that CPAP had any effect
on blood pressure in hypertensive patients with
somnolence.44 Moreover, in the meta-analyses, as
seen in our results, no clinical variables were found to
predict reductions in blood pressure with CPAP
treatment.19 However, the decrease in blood pressure
Table 3 | Results of 24 hour ambulatory blood pressure monitoring. Values are mean (SD) unless stated otherwise
Blood pressure measurement
CPAP group (n=169) Sham CPAP group (n=171)
Mean (SD) mm Hg
Effect size
(SD units) Mean (SD) mm Hg
Effect size
(SD units)
Baseline 6 weeks 12 weeks 6 weeks 12 weeks Baseline 6 weeks 12 weeks 6 weeks 12 weeks
Diurnal systolic blood pressure 135 (12) 132 (14)** 133 (13)* 0.25 0.19 132 (11) 132 (12) 132 (13) 0.02 0.06
Diurnal diastolic blood pressure 86 (8) 84 (9)** 84 (9)* 0.20 0.15 85 (9) 85 (9) 85 (10) −0.02 0.01
Diurnal mean blood pressure 102 (9) 100 (10)** 101 (10)* 0.24 0.18 101 (9) 101 (9) 100 (10) −0.01 0.03
Nocturnal systolic blood pressure 123 (13) 119 (15)** 119 (14)** 0.30 0.29 121 (14) 122 (15) 121 (15) −0.02 0.05
Nocturnal diastolic blood pressure 76 (9) 74 (10)** 74 (10)** 0.23 0.25 76 (10) 76 (10) 75 (10) −0.02 0.07
Nocturnal mean blood pressure 92 (10) 89 (11)** 89 (10)** 0.28 0.29 91 (11) 91 (11) 90 (10) −0.02 0.07
Mean 24 hour systolic blood pressure 131 (12) 128 (14)** 128 (13)** 0.28 0.24 129 (11) 129 (12) 128 (13) 0.00 0.06
Mean 24 hour diastolic blood pressure 83 (8) 81 (9)** 81 (9)** 0.23 0.20 82 (9) 82 (8) 82 (9) −0.03 0.03
Mean 24 hour blood pressure 99 (8) 96 (9)** 97 (9)** 0.27 0.24 97 (9) 98 (9) 97 (9) −0.01 0.05
No (%) hypertensive 108 (64) 93 (55)* 94 (56)* 96 (56) 98 (57) 89 (52)
No (%) non-dippers 109 (64) 97 (57) 94 (56)* 107 (63) 111 (65) 101 (59)
Epworth sleepiness scale (1-24) 10.4 (4.2) 7.6 (3.8)** 7.2 (3.7)** 0.65 0.74 9.8 (4.4) 8.9 (4.0)** 8.8 (4.2)** 0.21 0.22
EuroQol (visual analogue scale) 69 (15) 74 (14)** 76 (16)** 0.31 0.38 72 (17) 72 (16) 73 (15) 0.02 0.06
CPAP=continuous positive airway pressure.
*P<0.05 compared with baseline, calculated by paired t test for continuous variables or McNemar test for proportion of patients with hypertension and proportion of non-dippers.
**P<0.001 compared with baseline, calculated by paired t test.
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was greater in patients with better compliance with
CPAP.15 34
Classically, people have accepted that asymptomatic
patients treated with CPAP will probably have poor
compliance in the absence of noticeable benefits on
reduced hypersomnolence or improved quality of
life. Our patients were mildly sleepy, with a slight
increase in Epworth scores. They were patients with
obstructive sleep apnoea and untreated hypertension
recruited consecutively by general practitioners and
had acceptable compliance with CPAP and dropout
rates, similar to those of the sham group. However, a
remaining question is the feasibility of more than
12 weeks of CPAP treatment for this symptomless
hypertensive population. Barbé et al followed a large
sample of hypertensive, non-sleepy patients with
obstructive sleep apnoea for 12 months.34 The compli-
ance of the group treated with CPAP was 4.7 hours/
night, which was very similar to our own results, sug-
gesting that CPAP treatment is feasible in this popula-
tion.
Data from meta-analyses suggest that the beneficial
effects of CPAPon blood pressure are detectable in the
first few weeks of treatment,18-21 and few studies have
lasted more than 12 weeks.34-36 43 45 46 One could argue
that vascular remodelling and other structural cardio-
vascular changes would not be evident in short term
trials of CPAP treatment and that longer treatment
may be needed to obtain greater reductions in blood
pressure. However, results from randomised trials
have found significant reductions in blood pressure
with a few weeks of CPAP treatment.26 27 33 42 We also
found relevant decreases in bloodpressure at sixweeks
in the CPAP group compared with the sham group. In
spite of a non-significant decrease between weeks six
and 12, the effect was still present at the end of the
study.These data suggest that reductions in bloodpres-
sure are evident a few weeks after CPAP treatment.
The 24 hour ambulatory blood pressure monitoring
provides a measure of the patterns of blood pressure
during sleep. The prognostic value of night-time blood
pressure has been found to be superior to that of day-
time blood pressure.47 We found a net reduction for
nocturnal systolic blood pressure of 3.1 mm Hg,
which could have clinical significance. In addition, 24
hour ambulatory blood pressure monitoring allowed
us to identify non-dipping patients. In most people,
blood pressure drops by 10-20% during the night (dip-
pers), and people who do not show such reductions
seem to be at increased risk of cardiovascular
events,22 with a higher prevalence of organ damage
and less favourable outcomes.47 Most patients with
obstructive sleep apnoea have a non-dipping
pattern,47 and we found a statistically significant reduc-
tion in the percentage of non-dipping patients only in
theCPAPgroup. Similarly, only the group treatedwith
CPAP showed a statistically significant percentage
reduction in the number of patients with systemic
hypertension. These data, despite the small effect
size, could have a clinical effect.
CPAP has the well known effect of improving
Epworth sleepiness scores in both sleepy and non-
sleepy patients with obstructive sleep apnoea.16 24 34
Our patients were mildly sleepy, and both treatment
groups (CPAP and sham) improved significantly; this
shows the importance of doing a randomised con-
trolled trial, as any intervention can produce some
improvement. The effect was significantly greater in
the CPAP group, however. The EuroQol has been
shown to be an effective test for measuring quality of
life in patients with obstructive sleep apnoea,48 and our
results show a statistically significant improvement in
the EuroQol scores only in the CPAP group, although
we did not find any associations between compliance
with CPAP and EuroQol results. This might be caused
by good baseline results on the EuroQol test. On the
other hand, we found a good correlation between com-
pliance with CPAP and improvement in Epworth
scores, also suggested by other studies,16 which sup-
ports the hypothesis that symptomatic improvement
Table 4 | Compliance with treatment (intention to treat analysis)
Compliance
6 weeks 12 weeks
CPAP Sham CPAP P value* CPAP Sham CPAP P value*
Mean (SD) compliance (hours/night) 4.4 (1.8) 4.2 (1.9) 0.48 4.5 (1.7) 4.2 (1.8) 0.13
No (%) complied >3 hours/day 120 (71) 121 (71) 0.60 119 (70) 114 (67) 0.79
No (%) complied >4 hours/day 106 (63) 107 (63) 0.95 110 (65) 101 (59) 0.40
CPAP=continuous positive airway pressure.
























































Fig 2 | Change in 24 hour ambulatory blood pressure
monitoring (ABPM) values in each group after 12 weeks of
treatment. Daytime blood pressure was measured from 6 am
to 10 pm. Night-time blood pressure was measured from 10
pm to 6 am. Change was measured as mean pre-treatment
minus mean post-treatment values. Positive values favour
CPAP group. Bars represent mean and 95% CI. Results are by
intention to treat analysis. *Significant changes over time
(P<0.05)
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is associated with better compliance with CPAP. How-
ever, neither Epworth nor EuroQol scores were asso-
ciated with changes in blood pressure, suggesting that
such changes were poorly correlated with clinical
symptoms or quality of life in our patients.
Strengths and limitations of study
This study had several strengths that lend confidence
to our findings. Firstly, the sample was the largest mul-
ticentre trial to date, with 11 participating hospitals,
and used 24 hour ambulatory blood pressuremonitor-
ing. Secondly, all patients hadobstructive sleep apnoea
diagnosed by polysomnography with the same
method. Thirdly, patients had just been diagnosed as
having systemic hypertension and had received no
treatment other than conservative measures. We
believe that this is a key point, as it allowed us to
study the kind of patients that general practitioners
usually treat, not filtered by sleep clinics or hospitals.
Finally, the compliance in the sham CPAP group was
the same as in the treatment group.
Someweaknesses and caveats should bementioned.
Firstly, we do not have any data on the 94 patients who
refused to participate, and we cannot be sure about the
magnitude of potential bias. Secondly, CPAP was
titrated by using auto-CPAP and not by poly-
somnography. However, studies by our group have
shown that these systems are comparable.24 Thirdly,
the follow-up period was 12 weeks and may not be
completely representative of longer periods. Fourthly,
we used sham CPAP as a placebo, and we recognise
that despite all the measures we took to ensure ade-
quate blinding to allocation of patients, some patients
(probably, but not certainly, in the placebo group)
complained that they continued snoring. Perfect blind-
ingof the studygroups is almost impossiblewhenusing
sham CPAP as a placebo; although Farré et al found
that no variables change with a placebo mask,25 Rod-
way et al and Marshall et al found that variables may
change in association with sham CPAP.49 50 These
changes are generally small, however, with minimal
clinical significance, suggesting that the use of sham
CPAP as a placebo is supported in intervention studies
in patients with obstructive sleep apnoea.49 Fifthly, the
magnitude of the effect was small, raising the question
of howgreat a reduction inbloodpressure is needed for
it to be considered clinically relevant,51 although small
decreases in blood pressure (of around 2 mm Hg, as
seen in our study) might reduce cardiovascular risk.52
The effect was greater when we restricted the results to
patients who had systemic hypertension according to
the results of the 24 hour ambulatory blood pressure
monitoring or who complied well with treatment or
when we analysed the results by protocol. Finally, we
did not find any clinical variables to predict the change
in 24 hour ambulatory blood pressure monitoring
values after CPAP. The potential mechanism by
which CPAP treatment reduces blood pressure levels
to a different extent in different patients with obstruc-
tive sleep apnoea is therefore unclear and is probably
related to gene expression. Identifying specific mar-
kers for selecting subgroups of patients in which
blood pressure levels are expected to be reduced to a
greater extent with CPAP should be the next step.
Conclusions
In patients with both untreated systemic hypertension
and obstructive sleep apnoea, CPAP significantly
reduces blood pressure in addition to the well known
beneficial effects on obstructive sleep apnoea related
symptoms. This reduction was small and did not
show the 3 mm Hg drop in mean 24 hour ambulatory
blood pressure that the trial was powered to detect.
Consequently, these results may have uncertain clini-
cal relevance. However, taking into account the preva-
lence of hypertension and the likelihood of
comorbidities, the decrease in blood pressure,
although minimal, may be beneficial. The reduction
in blood pressure was higher in patients with systemic
hypertension diagnosed by 24 hour ambulatory blood
pressure monitoring (removing patients with “white
coat” systemic hypertension), and also in patients
who used CPAPmore than three hours a night. There-
fore, applying CPAP as a treatment or co-treatment in
patients with both conditions, regardless of symptoms,
could be useful in selected cases, although this needs to
be confirmedby further studies. In addition, our results
could also lead to comparative treatment trials
between CPAP and antihypertensive drugs, especially
in patients with different severities of systemic hyper-
tension and obstructive sleep apnoea.
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